{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:44:49Z","timestamp":1792291489311,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of chronic liver disease. Its high mortality and morbidity are mainly caused by non-hepatic comorbidities and their clinical complications. Accumulating evidence suggests an association between NAFLD and heart failure (HF), but large-scale data analyses from Germany are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Disease Analyzer database (IQVIA), this analysis retrospectively evaluated two cohorts of outpatients with and without NAFLD with respect to the cumulative incidence of HF as the primary outcome between January 2005 and December 2020. Cohorts were propensity score matched for sex, age, index year, yearly consultation frequency, and known risk factors for HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 173,966 patients were included in the analysis. Within 10\u00a0years of the index date, 13.2% vs. 10.0% of patients with and without NAFLD were newly diagnosed with HF (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). This finding was supported by univariate Cox regression analysis in which NAFLD was found to be significantly associated with subsequent HF (Hazard Ratio (HR) 1.34, 95% Confidence Interval (CI) 1.28\u20131.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The association between NAFLD and HF was observed across all analysed age groups and as comparable between both men (HR 1.30, 95% CI 1.23\u20131.38;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and women (HR: 1.37, 95% CI 1.29\u20131.45;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NAFLD is significantly associated with an increased cumulative incidence of HF, which, given its rapidly increasing global prevalence, could be crucial to further reduce its high mortality and morbidity. We recommend risk stratification within a multidisciplinary approach for NAFLD patients, including systematic prevention or early detection strategies for HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-023-02250-z","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T06:01:52Z","timestamp":1688623312000},"page":"1446-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Non-Alcoholic Fatty Liver Disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients"],"prefix":"10.1007","volume":"112","author":[{"given":"Christoph","family":"Roderburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-0304","authenticated-orcid":false,"given":"Sarah","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Vaghiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Konrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven H.","family":"Loosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"2250_CR1","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1002\/hep4.2081","volume":"6","author":"Y Lan","year":"2022","unstructured":"Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y et al (2022) Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China. Hepatol Commun 6:3393\u20133405","journal-title":"Hepatol Commun"},{"key":"2250_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209","journal-title":"J Hepatol"},{"key":"2250_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 69:896\u2013904","journal-title":"J Hepatol"},{"key":"2250_CR4","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","volume":"17","author":"Y Huber","year":"2019","unstructured":"Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C et al (2019) Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol 17:2085-2092.e2081","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2250_CR5","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E et al (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69:2672\u20132682","journal-title":"Hepatology"},{"key":"2250_CR6","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557\u20131565","journal-title":"Hepatology"},{"key":"2250_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138\u20131153","journal-title":"Gut"},{"key":"2250_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: jacc state-of-the-art review. J Am Coll Cardiol 73:948\u2013963","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"2250_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.14484","volume":"24","author":"CD Byrne","year":"2022","unstructured":"Byrne CD, Targher G (2022) Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 24(Suppl 2):28\u201343","journal-title":"Diabetes Obes Metab"},{"key":"2250_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","volume":"79","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G (2022) Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol 79:180\u2013191","journal-title":"J Am Coll Cardiol"},{"key":"2250_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG et al (2021) Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:903\u2013913","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2250_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6:578\u2013588","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2250_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G (2018) Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15:425\u2013439","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2250_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jhep.2019.01.035","volume":"70","author":"D Houghton","year":"2019","unstructured":"Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L et al (2019) The degree of hepatic steatosis associates with impaired cardiac and autonomic function. J Hepatol 70:1203\u20131213","journal-title":"J Hepatol"},{"key":"2250_CR15","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.numecd.2021.08.037","volume":"31","author":"G Targher","year":"2021","unstructured":"Targher G, Mantovani A, Grander C, Foco L, Motta B, Byrne CD et al (2021) Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic\/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutr Metab Cardiovasc Dis 31:3464\u20133473","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2250_CR16","doi-asserted-by":"publisher","first-page":"204062232211196","DOI":"10.1177\/20406223221119626","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Wen W, Xie D, Qiu M, Cai X, Zheng S et al (2022) Association between non-alcoholic fatty liver disease and risk of incident heart failure: a meta-analysis of observational studies. Ther Adv Chronic Dis 13:20406223221119624","journal-title":"Ther Adv Chronic Dis"},{"key":"2250_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/liv.12285","volume":"33","author":"MA Dunn","year":"2013","unstructured":"Dunn MA, Behari J, Rogal SS, O\u2019Connell MR, Furlan A, Aghayev A et al (2013) Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. Liver Int 33:1575\u20131582","journal-title":"Liver Int"},{"key":"2250_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 56:459\u2013466","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2250_CR19","doi-asserted-by":"crossref","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut 2022.","DOI":"10.1136\/gutjnl-2022-327672"},{"key":"2250_CR20","doi-asserted-by":"crossref","unstructured":"Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35:569\u2013582.","DOI":"10.1016\/S0735-1097(99)00630-0"},{"key":"2250_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12020-019-02070-0","volume":"66","author":"M Borges-Canha","year":"2019","unstructured":"Borges-Canha M, Neves JS, Lib\u00e2nio D, Von-Hafe M, Vale C, Ara\u00fajo-Martins M et al (2019) Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine 66:467\u2013476","journal-title":"Endocrine"},{"key":"2250_CR22","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/liv.14600","volume":"40","author":"LS Chiu","year":"2020","unstructured":"Chiu LS, Pedley A, Massaro JM, Benjamin EJ, Mitchell GF, McManus DD et al (2020) The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study. Liver Int 40:2445\u20132454","journal-title":"Liver Int"},{"key":"2250_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014279","volume":"9","author":"LB VanWagner","year":"2020","unstructured":"VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME et al (2020) Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. J Am Heart Assoc 9:e014279","journal-title":"J Am Heart Assoc"},{"key":"2250_CR24","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1002\/hep.32072","volume":"74","author":"J Zhou","year":"2021","unstructured":"Zhou J, Bai L, Zhang XJ, Li H, Cai J (2021) Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications. Hepatology 74:2839\u20132847","journal-title":"Hepatology"},{"key":"2250_CR25","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/aacf12","volume":"12","author":"PR Afolabi","year":"2018","unstructured":"Afolabi PR, Scorletti E, Smith DE, Almehmadi AA, Calder PC, Byrne CD (2018) The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the (13)C-ketoisocaproate breath test. J Breath Res 12:046002","journal-title":"J Breath Res"},{"key":"2250_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.omtn.2021.06.006","volume":"25","author":"LHH Aung","year":"2021","unstructured":"Aung LHH, Jumbo JCC, Wang Y, Li P (2021) Therapeutic potential and recent advances on targeting mitochondrial dynamics in cardiac hypertrophy: a concise review. Mol Ther Nucleic Acids 25:416\u2013443","journal-title":"Mol Ther Nucleic Acids"},{"key":"2250_CR27","doi-asserted-by":"crossref","unstructured":"Climent M, Viggiani G, Chen YW, Coulis G, Castaldi A. MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases. Int J Mol Sci 2020; 21.","DOI":"10.3390\/ijms21124370"},{"key":"2250_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel VB, Zhong JC, Grant MB, Oudit GY (2016) Role of the ACE2\/Angiotensin 1\u20137 axis of the renin-angiotensin system in heart failure. Circ Res 118:1313\u20131326","journal-title":"Circ Res"},{"key":"2250_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/gut.2010.214577","volume":"59","author":"AR Moschen","year":"2010","unstructured":"Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259\u20131264","journal-title":"Gut"},{"key":"2250_CR30","first-page":"4196","volume":"82","author":"V Mohamed-Ali","year":"1997","unstructured":"Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196\u20134200","journal-title":"J Clin Endocrinol Metab"},{"key":"2250_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3350\/cmh.2020.0129","volume":"27","author":"E Jennison","year":"2021","unstructured":"Jennison E, Byrne CD (2021) The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 27:22\u201343","journal-title":"Clin Mol Hepatol"},{"key":"2250_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/QCO.0000000000000759","volume":"34","author":"JS Jacob","year":"2021","unstructured":"Jacob JS, Ahmed A, Cholankeril G (2021) The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. Curr Opin Infect Dis 34:477\u2013482","journal-title":"Curr Opin Infect Dis"},{"key":"2250_CR33","doi-asserted-by":"crossref","unstructured":"Zhao Y, Wang Z. Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease. J Lab Precis Med 2020; 5.","DOI":"10.21037\/jlpm.2020.01.01"},{"key":"2250_CR34","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","volume":"38","author":"GG Schiattarella","year":"2017","unstructured":"Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A et al (2017) Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J 38:2948\u20132956","journal-title":"Eur Heart J"},{"key":"2250_CR35","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/apt.15738","volume":"51","author":"B Carlsson","year":"2020","unstructured":"Carlsson B, Lind\u00e9n D, Brol\u00e9n G, Liljeblad M, Bjursell M, Romeo S et al (2020) Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 51:1305\u20131320","journal-title":"Aliment Pharmacol Ther"},{"key":"2250_CR36","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40:1461\u20131465","journal-title":"Nat Genet"},{"key":"2250_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.27556","volume":"61","author":"S Sookoian","year":"2015","unstructured":"Sookoian S, Casta\u00f1o GO, Scian R, Mallardi P, Fern\u00e1ndez Gianotti T, Burgue\u00f1o AL et al (2015) Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61:515\u2013525","journal-title":"Hepatology"},{"key":"2250_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M (2017) Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 67:829\u2013846","journal-title":"J Hepatol"},{"key":"2250_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol 7:367\u2013378","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2250_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:262\u2013276","journal-title":"Lancet"},{"key":"2250_CR41","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s10620-021-06954-y","volume":"66","author":"B Zou","year":"2021","unstructured":"Zou B, Yeo YH, Cheung R, Ingelsson E, Nguyen MH (2021) Fatty liver index and development of cardiovascular disease: findings from the UK Biobank. Dig Dis Sci 66:2092\u20132100","journal-title":"Dig Dis Sci"},{"key":"2250_CR42","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF (2022) Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 71:1867\u20131875","journal-title":"Gut"},{"key":"2250_CR43","doi-asserted-by":"crossref","unstructured":"Roderburg C, Kostev K, Mertens A, Luedde T, Loosen SH. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer. Gut 2022.","DOI":"10.1136\/gutjnl-2022-328887"},{"key":"2250_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1055\/a-1378-4679","volume":"130","author":"C Labenz","year":"2022","unstructured":"Labenz C, Kostev K, Alqahtani SA, Galle PR, Schattenberg JM (2022) Impact of non-alcoholic fatty liver disease on metabolic comorbidities in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 130:172\u2013177","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2250_CR45","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1002\/ehf2.13421","volume":"8","author":"C Roderburg","year":"2021","unstructured":"Roderburg C, Loosen SH, Jahn JK, G\u00e4nsbacher J, Luedde T, Kostev K et al (2021) Heart failure is associated with an increased incidence of cancer diagnoses. ESC Heart Fail 8:3628\u20133633","journal-title":"ESC Heart Fail"},{"key":"2250_CR46","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/eurjpc\/zwab048","volume":"29","author":"SH Loosen","year":"2022","unstructured":"Loosen SH, Roderburg C, Jahn JK, Joerdens M, Luedde T, Kostev K et al (2022) Heart failure and depression: a comparative analysis with different types of cancer. Eur J Prev Cardiol 29:e112\u2013e114","journal-title":"Eur J Prev Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02250-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02250-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T11:02:44Z","timestamp":1696849364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02250-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02250-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Patient data were analyzed in aggregated form without individual health data being available. Individual informed consent was therefore not obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}},{"value":"The \"Disease Analyzer\" database, used for analysis, contains anonymized electronic patient records. Patient data were analyzed in aggregated form without individual data being available. An individual consent form was not obtained following national and European legislation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The \u201cDisease Analyzer\u201d database, used for analysis, contains anonymized electronic patient records. Patient data were analyzed in aggregated form without individual health data being available. An individual consent form was not obtained following national and European legislation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}}]}}